Navigation Links
Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimer's Association International Conference on Alzheimer's Disease
Date:7/8/2010

2010 highlights Pfizer's strategic approach to the discovery and development of potential new medicines as it underscores our effort to focus on a range of promising pathological targets.  We are committed to advancing the science of AD, with the ultimate goal of delivering innovative and meaningful new treatment options to patients."

The compounds in Pfizer's pipeline target many of the pathways thought to be implicated in Alzheimer's disease.  The data that will be presented at ICAD 2010 focus on several of these approaches, including:

Beta Amyloid Passive Immunotherapy: The most prominent theory currently is the beta amyloid hypothesis, which is based on evidence that the accumulation of beta amyloid, a toxic protein, is a defining characteristic of AD.  It is believed that reducing brain beta amyloid accumulation by inhibiting the production of beta amyloid and/or removing beta amyloid from the brain may slow the progression of the disease.  In passive immunotherapy, monoclonal antibodies are directed against beta amyloid facilitating removal of beta amyloid and thus reducing its accumulation in the brain.

Pfizer, together with Janssen Alzheimer Immunotherapy, its collaborator on the Alzheimer's Immunotherapy Program, is presenting a new exploratory analysis of pooled data from two Phase II studies on an investigational monoclonal antibody therapy.  Pfizer also is presenting several Phase I studies on another investigational monoclonal antibody therapy.

PDE Inhibition: The PDE enzyme family is thought to play a role in influencing synapse communication and stability, which is compromised in Alzheimer's disease.  Regulating the actions of these enzymes may potentially improve information processing, attention, memory and executive functioning.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Oct. 20, 2014 Pharmaceutic Labs announces the ... Albany, NY for admixing, compounding, ... meets and/or exceeds the FDA standards for safety and ... Part 211. The 10,000 square foot ... of quality assurance and quality control. The company will ...
(Date:10/19/2014)... Wash. , Oct. 20, 2014 CTI ... that it will report its third quarter 2014 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
(Date:10/17/2014)... , Oct. 17, 2014  Training market ... a critical success factor in today,s highly competitive ... market research organizations that effectively and efficiently produce ... or service area. Effective training ... and earn recognition from internal clients by developing ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... Keystone Symposia HIV Pathogenesis Conference, SAN ... ANX ) announced that it presented ... product candidate at the,Keystone Symposia HIV Pathogenesis ... The preclinical results demonstrate a unique resistance ...
... question with today,s ... ... uses a combination of catheter-mounted balloons and stents,to open a completely ... the best treatment for heart attack when performed rapidly.,However, few hospitals ...
Cached Medicine Technology:ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 2ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 3ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 4Is PCI Safe, Effective After Clot-Busters for Heart Attack? 2Is PCI Safe, Effective After Clot-Busters for Heart Attack? 3
(Date:10/19/2014)... been working in the garment industry for decades, LunaDress’ dress ... James, one of the company’s top designers, many ladies like ... that add beauty to them. Chiffon floor length outfits are ... new selection of 2014 long prom dresses. , As ... available in over 20 popular designs. The company intends to ...
(Date:10/19/2014)... 20, 2014 Recently, Fancyflyingfox.com, an innovative ... clothes, has announced its latest designs of 2014 ... the new elegant outfits are offered with big discounts, ... order before October 30 can enjoy this special offer. ... marketing strategies, it has become one of the leading ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Visual ... program has just been released to the public ... online body building and fitness community. The commotion ... of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. ... of hitting what is commonly known as a ...
(Date:10/19/2014)... 2014 (HealthDay News) -- New stem cell-based research could ... new treatments, a new study suggests. Scientists used ... tissue in a lab dish. They then transplanted the ... intestinal disorders, according to the researchers. "This provides ... conditions that can cause intestinal failure, from genetic disorders ...
(Date:10/19/2014)... 20, 2014 – The U.S. Government has initiated ... Alzheimer,s disease by 2025. However, a workgroup of ... research milestones in the U.S. Government,s National Plan ... scope, increased in scale, and adequately funded in ... of proposals by the workgroup to enlarge and ...
Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... MA Coronary heart disease (CHD) is the leading cause ... and economic costs, especially among older adults. It has ... least in middle-aged, low- and moderate-risk white men. Now ... Journal of the American College of Cardiology reports ...
... "Performance Excellence and Accountability in Kidney Care" to reduce mortality by ... , , WASHINGTON, June 8 ... campaign pledging to reduce mortality among first-year dialysis patients - those ... by 20 percent by the end of 2012. , ...
... electrical stimulation to prevent airway closure during sleep , ... Inc., a private medical device company, today announced it ... Earlier in 2009, Inspire announced the first human ... Obstructive Sleep Apnea (OSA). Since this announcement, Inspire ...
... depression and anxiety, research suggests , MONDAY, June 8 (HealthDay ... caregivers who may need a break. For children aged 4 ... help reduce hyperactivity, anxiety and depression, new study findings show. ... napping (77 percent) or non-napping (23 percent), researchers found that ...
... SEEKS INVOLVEMENT ACROSS THE UNITED STATES; ASKS PUBLIC TO DIRECT ... June 8 Tom,s of Maine introduces 50 States for ... difference in their communities. The national program asks the public ... lasting, positive change. , , Tom,s of Maine ...
... of Arts and Sciences has published a volume of ... Questions," examining the scientific support for using functional magnetic ... seven essays, authored by scholars of neuroscience, law, and ... when machine-based means are employed to identify deceit. ...
Cached Medicine News:Health News:Cardiac rehabilitation saves lives 2Health News:Rep. Lewis Commends Kidney Care Partners' Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients in Georgia 2Health News:Rep. Lewis Commends Kidney Care Partners' Health Care Campaign to Improve Survival Rates of First-Year Dialysis Patients in Georgia 3Health News:Inspire Medical Systems Completes $17 Million Series B Financing 2Health News:Inspire Medical Systems Completes $17 Million Series B Financing 3Health News:Tom's of Maine Invites Public Participation in 50 States for Good Program 2Health News:New essays examine the use of fMRI to recognize deceit 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: